top of page
  • Writer's pictureJinks Crow

FDA Issues Safety Communication for BioZorb Markers and Potential Risks with Use in Breast Tissue



As a result of the ongoing litigation by Jinks Crow, the FDA has issued a safety communication regarding Biozorb® markers and potential risks with use in breast tissue.



If you or a loved one was implanted with a Biozorb® device as part of treatment for breast cancer and has experienced any of the above injuries, please contact Jinks Crow & Dickson for a free consultation with an attorney.





Comments


bottom of page